China Universal Asset Management Co. Ltd. Purchases 663 Shares of argenx SE (NASDAQ:ARGX)

China Universal Asset Management Co. Ltd. lifted its position in shares of argenx SE (NASDAQ:ARGX) by 10.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,837 shares of the company’s stock after buying an additional 663 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in argenx were worth $4,205,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ARGX. Cromwell Holdings LLC raised its stake in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares in the last quarter. GAMMA Investing LLC grew its position in argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares in the last quarter. SG Americas Securities LLC increased its stake in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after acquiring an additional 21 shares during the period. Fulton Bank N.A. acquired a new position in argenx in the 4th quarter valued at $226,000. Finally, Blue Trust Inc. lifted its position in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after acquiring an additional 298 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Performance

argenx stock opened at $655.13 on Friday. The firm has a 50 day moving average price of $632.58 and a two-hundred day moving average price of $569.61. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter last year, the firm posted ($1.25) EPS. Equities analysts expect that argenx SE will post 2.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Raymond James restated a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. Guggenheim lifted their price objective on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Robert W. Baird downgraded argenx from an “outperform” rating to a “neutral” rating and upped their price objective for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $675.00 price target (up from $646.00) on shares of argenx in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.